Join
Live feed
·
PRReleasevia Quantisnow
Perspective Therapeutics Inc. logo

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

ByQuantisnow·Wall Street's wire, on your screen.
CATX· Perspective Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CATX (Perspective Therapeutics Inc.) and more on Quantisnow.